$63.480
0.000 (0.00%)Al cierre
Noticias de CTLT
Eventos de CTLT
Silexion Therapeutics enters collaboration with Catalent
Silexion Therapeutics (SLXN) announced a strategic collaboration with Catalent (CTLT). Under the agreement, Catalent will conduct formulation development and clinical manufacturing activities for Silexion's next-generation siRNA candidate, SIL204, at its facility in Limoges, France. The collaboration will focus on optimizing both the systemic and intratumoral delivery formulations of SIL204, supporting Silexion's recently announced dual-route development strategy designed to target both primary tumors and metastases in KRAS-driven cancers. Catalent's Limoges facility is its European center of excellence for clinical biologics formulation development and drug product manufacturing, specializing in complex injectable formulations. The collaboration will leverage Catalent's extensive experience in developing sustained-release technologies to enhance SIL204's therapeutic potential through improved stability, bioavailability, and delivery precision.This collaboration is part of Silexion's comprehensive strategy to advance SIL204 through preclinical development and into clinical trials, with plans to conduct additional toxicology and pharmacodynamic studies throughout 2025, followed by potential regulatory submissions to the Israel Ministry of Health in the second half of 2025 and to the European Union in the first half of 2026.
Lennox to replace Catalent in S&P 500 at open on 12/23
Novo Holdings (NVO) has acquired Catalent (CTLT) in a deal that closed on December 18.
Lennox to replace Catalent in S&P 500 at open on 12/23
Novo Holdings (NVO) has acquired Catalent (CTLT) in a deal that closed on December 18.
Novo says Catalent deal regulatory closing conditions fulfilled
Novo Nordisk (NVO) announced that as of today, all regulatory closing conditions relating to the review of its pending acquisition of Catalent (CTLT), including expiry of the timing agreement in the U.S., have been fulfilled. The parties are now free to close the transaction, as well as Novo Nordisk's subsequent acquisition of three Catalent manufacturing sites from Novo Holdings. Novo Nordisk now expects the acquisition to be completed in the coming days. Upon completion, the acquisition is expected to impact Novo's financial outlook as issued on November 6, with a low single-digit negative impact on operating profit growth and to negatively impact free cash flow with the $11.7B acquisition price. The company said its ongoing share buyback program of 20B DKK is not impacted. For 2025, the acquisition is expected to have a mid single-digit negative impact on operating profit growth. Novo Nordisk added that its capital allocation priorities focus on internal growth investments, including supply chain expansions, dividends as well as external growth opportunities, including acquiring the three manufacturing sites. Consequently, Novo is not expecting to initiate a share buyback program in 2025. f
EU approves Novo Holdings' acquisition of Catalent
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of Catalent (CTLT) by Novo Holdings. The Commission concluded that the transaction would not raise competition concerns in the European Economic Area. Novo Holdings is the ultimate owner of Novo Nordisk (NVO). The Commission concluded that the proposed merger would not raise competition concerns on any of the markets examined in the EEA or on any substantial part of it. It therefore cleared the transaction unconditionally.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.